#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endo International Q3 revenue increased 18.6%

Share on Twitter Share on LinkedIn
Staff Writer | November 8, 2016
International reported an 18.6 percent rise in quarterly revenue, driven by higher demand for generic drugs it acquired through its purchase of Par Pharmaceuticals last year.
Endo International   Total revenue rose to $884.3 million
The Dublin, Ireland-based drugmaker's net loss attributable to shareholders narrowed to $218.9 million, or 98 cents per share, in the third quarter ended Sept. 30, from $1.05 billion, or $5.02 per share, a year earlier.

Total revenue rose to $884.3 million from $745.7 million.